Biocon has received approval in India for its generic version of Victoza, marking its first GLP-1 diabetes therapy clearance and strengthening its push into a fast-growing treatment category.
Biocon has received approval in India for its generic version of Victoza, marking its first GLP-1 diabetes therapy clearance and strengthening its push into a fast-growing treatment category.